Bavarian Nordic will supply its smallpox vaccine Imvanex to at least two countries as cases of monkeypox surge in Europe and elsewhere.

Dan Stanton, Managing editor

May 27, 2022

2 Min Read
Bavarian Nordic to respond to monkeypox threat with vaccine supply
Image by Sakurai Midori - creative commons, Wikipedia

Bavarian Nordic will supply its smallpox vaccine Imvanex to at least two countries as cases of monkeypox surge in Europe and elsewhere.

The surge of cases of monkeypox outside west and central Africa have alarmed health authorities over the past few weeks. While some commentators claim the outbreak is nothing to be too concerned about, some governments have looked to secure vaccinations in order to mitigate against a potential epidemic.

There is no official vaccine for monkeypox in Europe, but a smallpox jab offers up to 85% protection. As such, Danish drugmaker Bavarian Nordic has signed at least two contracts with governments to supply its approved MVA-BN, or Modified Vaccinia Ankara-Bavarian Nordic, vaccine.


Image by Sakurai Midori – creative commons, Wikipedia

Known as Imvanex in Europe, Jyneos in the US (where it was approved in 2019 specifically for monkeypox), and Imvamune in Canada, the vaccine is a live, attenuated virus grown in cell lines derived from chicken eggs, made at Bavarian Nordic’s large-scale facility in Kvistgaard, Denmark.

The first order was announced eight days ago with an undisclosed European government, but the deal was not expected to impact the company’s 2022 guidance.

A second deal, announced with another country, was announced Wednesday and will  affect Bavarian Nordic’s forecasting, adding around DKK 200 million ($29 million) to the firm’s projected 2022 revenues.

“The current monkeypox outbreak, which is now affecting countries globally, calls for a swift and coordinated response from health authorities, and we are pleased to assist another country with supply of vaccines to fulfil a growing demand,” Bavarian Nordic CEO Paul Chaplin said in a statement.

“Building on our vast experience and relations with governments in the procurement of vaccines for their national preparedness, we have rapidly adapted to this unprecedented situation and are working closely with other governments to make vaccines available as fast as possible to mitigate the situation.”

While the government tenders have not been identified, French news outlet RFi reported this week French and Danish health authorities want to start a vaccination campaign targeting adults who have been exposed to monkeypox.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like